Equity
€11.68bn ▲ 11.6%
Janssen Pharmaceutica has made a profit without a break since 2010.
Janssen Pharmaceutica
Part of the group
13 companies in 6 countries
Lifetime
17 annual accounts with figures on one time axis, 49 filings since 1977peak €22.59bn (2024)
€21.79bn▼ 3.5%
lowest -€4.2m (2009)
€1.46bn▼ 44.5%
peak €12.24bn (2020)
€11.68bn▲ 11.6%
€9.34bn▼ 6.4%
peak 5,324.5 FTE (2025)
5,324.5 FTE▲ 2.2%
Board87 names since 2004all names
14 directors and 13 others
Owners2 names in the annual accounts
99.99% and 1 other
Documentsfilings and deeds
22-06-202639 days before the deadline
2025financial year
Result from €2.63bn to €1.46bnResignation: (managing director) 22-127 directors appointed, 2 resignations 27-11Appointment: (director) 03-11Powers of attorney: , and 45 others 21-10Dividend €250.0m
Key points
from the 2025 annual accountsResult
€1.46bn ▼ 44.5%
The result fell in 2025 from €2.63bn to €1.46bn.
Group
7 companies controlled
Heads a group. Known shareholders 100%.
Board
3 joined · 4 left
Board changed. Latest change 03-11-2026 · 14 in office.
Position in the sector
€1.46bn
Higher net result than 95% of companies in pharmaceuticals. Sector median €981,635 · 60 companies.
Public support
€42.7m awarded from 2022 to 2025
Flemish support, mostly Onderzoeksproject.
Standalone figures, without subsidiaries
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 322 companies had the same profile as Janssen Pharmaceutica has now. Each dot is one company, two years later.
97.5%
were still trading
2.5%
stopped another way
0.0%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 322 companies, not a prediction for Janssen Pharmaceutica. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Chair
Managing director
Director
Director, since 01-11-2022
Director, since 01-03-2023
Auditor,
- 99.99%annual accounts 2025
- 0.01%annual accounts 2025
Shares in 9 companies, including and .
Board & ownershipRecent changes
Resignation: (director)
Appointment: (director) · Director discharge: · General meeting of 21-10-2026 · Gazette deed
Share transfer
holds all the shares · Gazette deed
Environmental permit granted
Bouwen of herbouwen, Nieuwbouw of aanleggen · Provincie Antwerpen
Environmental permit granted
Nieuwbouw of aanleggen, Nieuwbouw van bijgebouwen, niet-overdekte lage constructies en andere handelingen · Machelen
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Janssen Pharmaceutica Beerse | €21,788.2m | 6.8% | 54.1% | 5,324.5 |
| GlaxoSmithKline Biologicals Rixensart | €7,439.8m | 35.2% | 55.9% | 8,371 |
| UCB PHARMA Anderlecht | €4,622.6m | 7.2% | 78.3% | 1,960.6 |
| PFIZER MANUFACTURING BELGIUM Puurs-Sint-Amands | €1,022.7m | 13.9% | 76.7% | 4,020.8 |
| UCB BIOPHARMA Anderlecht | €3,642.1m | 3.7% | 16.4% | 1,395.2 |
Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as Janssen Pharmaceutica: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €2.5bn and €21bn, founded between 1960 and 2013.
Official details
Source: KBO- Status
- Active since 23-10-1934Normal situation
- Registered office
- 11 active companies are registered at this addressSource: KBO register, as of 13 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 2 others
- Joint committees
- 100Auxiliary committee for blue-collar workers
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment units
- 2.104.895.9412250 Olen, since 01-01-1800
- 2.142.774.7382440 Geel, since 01-01-1945and 10 others
- Financial year end
- 31 December
- Peppol
- Reachable since 18-12-2025
Annual accounts 2025
- €21.58bn▲ 3.0%
- Employeeson 31-12-2025
- 5,572▲ 2.5%
- Filing
- Filed on 22-06-2026, 39 days before the end of the filing period
Companies linked to Janssen Pharmaceutica
Subsidiaries and holdings
- 99.99%
- 99%
- 0.01%
Insights on Janssen Pharmaceutica
Janssen Pharmaceutica has existed since 1934. Turnover grew from €1.79bn in 2008 to €21.79bn in 2025 and staff from 4,082.3 to 5,324.5 full-time equivalents.
holds all the shares. In 2024, five directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Janssen Pharmaceutica
- What is the company number of Janssen Pharmaceutica?
- The company number of Janssen Pharmaceutica is 0403.834.160. The VAT number is the same number with BE in front: BE 0403.834.160.
- Where is Janssen Pharmaceutica based?
- The registered office is at Turnhoutseweg 30, 2340 Beerse.Company details
- What does Janssen Pharmaceutica do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of Janssen Pharmaceutica?
- Janssen Pharmaceutica is a public limited company (NV).
- When was Janssen Pharmaceutica founded?
- Janssen Pharmaceutica was founded on 23-10-1934.
- Is Janssen Pharmaceutica still active?
- Yes, Janssen Pharmaceutica is an active enterprise in the KBO register.
- How many employees does Janssen Pharmaceutica have?
- Janssen Pharmaceutica had an average of 5,324.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Janssen Pharmaceutica fall under?
- In its 2025 annual accounts, Janssen Pharmaceutica states joint committees 100 (Auxiliary committee for blue-collar workers) and 207 (White-collar workers in the chemical industry).
- What is the turnover of Janssen Pharmaceutica?
- The turnover of Janssen Pharmaceutica was €21.79bn in financial year 2025, according to the filed annual accounts.
- Is Janssen Pharmaceutica profitable?
- In financial year 2025, Janssen Pharmaceutica made a profit of €1.46bn.
- Where can I find the annual accounts of Janssen Pharmaceutica?
- Janssen Pharmaceutica filed 84 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Janssen Pharmaceutica due?
- Janssen Pharmaceutica must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.